Business Segments · Restructuring cost incurred to date
Business Segments — Restructuring cost incurred to date
Pfizer Business Segments — Restructuring cost incurred to date increased by 120.0% to $3.30B in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ4 2021
Last reportedQ1 2026
Rolls up toCumulative Cost Basis
How to read this metric
High costs indicate active efforts to streamline operations, which may lead to improved long-term profitability.
Detailed definition
The cumulative financial impact of restructuring activities already executed within the biopharmaceutical segment. It re...
Peer comparison
Standard metric for tracking the execution phase of corporate transformation projects in the pharma industry.
Metric ID:
pfe_segment_biopharma_restructuring_cost_incurred_to_dateHistorical Data
6 periods
| Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $856.00M | $1.40B | $1.40B | $1.50B | $1.50B | $3.30B |
| QoQ Change | — | +63.6% | +0.0% | +7.1% | +0.0% | +120.0% |
| YoY Change | — | +63.6% | — | — | — | — |
Range$856.00M – $3.30B
CAGR+194.3%
Avg YoY Growth+63.6%
Median YoY Growth+63.6%
Current Streak5+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — restructuring cost incurred to date?
- Pfizer (PFE) reported business segments — restructuring cost incurred to date of $3.30B in Q1 2026.
- What does business segments — restructuring cost incurred to date mean?
- The total costs already spent on restructuring the biopharma business.